Skip to content
value.today

Exicure, Inc.

XCUR
$6 Mmarket cap on Oct 30, 2026+18.6% since Jan 2024
Compare
World rank
#26,753
Revenue
—
For year ending December-2025
Net income
$-5 M
SEC filing
Employees
—

Exicure, Inc. in brief

Exicure, Inc. is a listed company in the Biotechnology industry, based in Chicago, Illinois, USA. It was founded in 2011. Its market value was $6 M on 30 October 2026, which makes it the 26,753rd largest listed company in the world and the 4,383rd largest in the USA on this site. Its largest business segments by sales in 2024 were Biotechnology (100%). Its shares trade under the symbol XCUR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Exicure, Inc.

Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. In February 2024, we received an upfront payment of $500,000 from a licensing agreement for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will be material. In the second quarter of 2024, we recognized other income of $637,000 from the sale of our samples related to the licensed product. In the third quarter of 2024, we sold our historical biotechnology intellectual property and other assets (including the licensing agreement described above) pursuant to the purchase agreement and recognized other income of $1,500,000. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.

From the company's annual report filed with the US SEC: read the report

Exicure, Inc. timeline

4 events, 2011–2022
  1. 2011
  2. 🏁
    · approximate
    Founded
  3. 2017
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. ✎
    Renamed Exicure, Inc.
    Formerly Max-1 Acquisition Corp.
  6. 2022
  7. 💰
    Record revenue of $29 million
    FY2022, the highest of the 5 years on record.

Events of Exicure, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$60 M$120 M$180 M$240 M2020202120222023202420252026

World rank over time

▼ down 11,352 places since 2020
2020-01-01: #15409#15,40920202021-01-01: #16427#16,42720212022-01-07: #30316#30,31620222022-12-25: #32408#32,40820222023-07-30: #31907#31,90720232024-01-05: #32334#32,33420242026-03-08: #11789#11,78920262026-08-01: #23191#23,19120262026-10-14: #26361#26,36120262026-10-30: #26761#26,7612026

Rank in USA: #3,157 (Jan 2020) · #3,401 (Jan 2021) · #5,361 (Jan 2022) · #5,721 (Dec 2022) · #5,458 (Jul 2023) · #4,630 (Jan 2024) · #2,277 (Mar 2026) · #4,073 (Aug 2026) · #4,293 (Oct 2026) · #4,385 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.5×
Free cash flow yield
-144.4%
Net margin
—
Operating margin
—
Return on equity
-126.0%
Liabilities / assets
72.1%
Net debt
$-28M
Revenue growth
-98.3%
R&D / revenue
0.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-22M$0MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-26M$1MFY19Fiscal year ending Dec 2020: revenue $17M, net income $-25M$17MFY20Fiscal year ending Dec 2021: revenue —, net income $-64M—FY21Fiscal year ending Dec 2022: revenue $29M, net income $-3M$29MFY22Fiscal year ending Dec 2023: revenue —, net income $-17M—FY23Fiscal year ending Dec 2024: revenue $1M, net income $-10M$1MFY24Fiscal year ending Dec 2025: revenue —, net income $-5M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-4M$-5M—
Dec 2024$1M—$-12M$-10M-1940.0%
Dec 2023——$-15M$-17M—
Dec 2022$29M—$-2M$-3M-8.9%
Dec 2021——$-63M$-64M—
Dec 2020$17M+1177.7%$-25M$-25M-148.5%
Dec 2019$1M+983.3%$-27M$-26M-2023.1%
Dec 2018$0M—$-22M$-22M-18675.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-9M$0M$-9M$-0.79—
Dec 2024$-3M$0M$-3M$-4.75—
Dec 2023$-10M$0M$-10M$-10.55—
Dec 2022$-36M$0M$-36M$-0.56—
Dec 2021$-35M$1M$-36M$-21.70—
Dec 2020$-39M$3M$-42M$-0.28—
Dec 2019$1M$1M$0M$-0.46—
Dec 2018$-19M$0M$-20M$-0.54—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-1M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-7M—Dec ’24Three months to Mar 2025: revenue —, net income $3M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-1M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Exicure, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-4 M
Net income
$-5 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$14 M
Total liabilities
$10 M
Total equity
$4 M

As of December-2025

Top 18 institutional investors in Exicure, Inc.#

As of Sep 30, 2026
18 institutions held 203,717 shares (about 3.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 3.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 18 largest institutional investors in Exicure, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Citadel Advisors LLC85,993+71,074 (+476.40%)1.35%$0 MNov 16, 2026
2Geode Capital Management, LLC40,409+9,160 (+29.31%)0.63%$0 MNov 6, 2026
3Vanguard Capital Management LLC28,883-14,228 (-33.00%)0.45%$0 MNov 13, 2026
4Two Sigma Investments, LP13,259New0.21%$0 MNov 16, 2026
5Virtu Financial LLC13,250New0.21%$0 MNov 17, 2026
6Vanguard Fiduciary Trust Co13,1610 (0.00%)0.21%$0 MNov 13, 2026
7Tower Research Capital LLC (TRC)5,042+968 (+23.76%)0.08%$0 MNov 16, 2026
8UBS Group AG3,149+2,807 (+820.76%)0.05%$0 MNov 10, 2026
9SBI Securities Co., Ltd.243+200 (+465.12%)0.00%$0 MOct 22, 2026
10Morgan Stanley138-5 (-3.50%)0.00%$0 MNov 13, 2026
11Royal Bank Of Canada820 (0.00%)0.00%$0 MNov 16, 2026
12BlackRock, Inc.350 (0.00%)0.00%$0 MNov 13, 2026
13Osaic Holdings, Inc.290 (0.00%)0.00%$0 MNov 12, 2026
14Prestige Wealth Management Group LLC200 (0.00%)0.00%$0 MNov 16, 2026
15Harbour Investments, Inc.170 (0.00%)0.00%$0 MNov 9, 2026
16BNP Paribas Financial Markets40 (0.00%)0.00%$0 MNov 12, 2026
17Jpmorgan Chase & Co20 (0.00%)0.00%$0 MNov 12, 2026
18Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Exicure, Inc.#

7 funds hold shares worth $0 M (about 1.2% of the company). Since their previous reports 2 added shares and 2 sold, selling $0 M net.
Mutual funds holding Exicure, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC19,367$0 M0.30%<0.01%+24%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.28,883$0 M0.45%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.14,228$0 M0.22%<0.01%+247%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC4,731$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC3,639$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,912$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors35$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Exicure, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$11.6 M
4 sales, 2 insiders
Net, 12 months
-$11.6 M
open market only
Insiders on file
20
since
$8.7 M-$7.8 M$0Feb 2024: bought $0 (0 trades), sold $4.5 M (1 trades)Feb 24Sep 2024: bought $712 K (1 trades), sold $0 (0 trades)SepDec 2024: bought $8.7 M (1 trades), sold $0 (0 trades)DecDec 2025: bought $0 (0 trades), sold $3.8 M (1 trades)DecJan 2026: bought $0 (0 trades), sold $7.8 M (3 trades)Jan 26
Bought (open market)Sold (open market)Hover a month for the totals
Exicure, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Exicure HiTron Inc.10% ownerOther+117,441$4.500$528 K2.22 MForm 4
filed Exicure HiTron Inc.10% ownerOther+253,195$4.500$1.1 M2.10 MForm 4
filed Exicure HiTron Inc.10% ownerOther+123,456$4.500$556 K1.85 MForm 4
filed Exicure HiTron Inc.10% ownerOther+129,183$4.500$581 K1.73 MForm 4
filed Josh MillerChief Accounting OfficerShares withheld for tax-8$4.080$33301Form 4
filed Exicure HiTron Inc.10% ownerSell-258,367$4.500$1.2 M1.60 MForm 4
filed Exicure HiTron Inc.10% ownerSell-734,747$4.500$3.3 M1.86 MForm 4
filed Exicure HiTron Inc.10% ownerSell-741,272$4.500$3.3 M2.59 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Exicure, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
52,218
0.8% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-5 reverse split ; 1-for-30.03 reverse split

Trading halts

  • 2025-12-05 15:56 UTC, code LUDP, resumed 16:01 UTC
  • 2025-07-03 14:12 UTC, code LUDP, resumed 14:22 UTC
  • 2025-01-17 14:53 UTC, code LUDP, resumed 14:58 UTC
  • 2024-12-04 14:32 UTC, code LUDP, resumed 14:37 UTC
  • 2024-12-03 14:39 UTC, code LUDP, resumed 14:44 UTC

Fails to deliver

  • : 3,652 shares at $0.93
  • : 238 shares at $1.07
  • : 3,783 shares at $1.05
  • : 904 shares at $1.13
  • : 301 shares at $1.04

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Exicure, Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-144.3%Free cash flow is -144.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.79 vs -4.75Diluted EPS -0.79 in fiscal 2025 against -4.75 the year before (report's currency).
    • ✓Net income higher than five years earlier-$5 M-$5 M in fiscal 2025 against -$25 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-92.5%-92.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.19 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year208.2%Diluted shares up 208.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Exicure, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Exicure, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00.5029−0.5171.30.19.71.0
Research and development3.301.4204932191413r14
General and administrative6.85.412r111310.08.67.87.03.5
Operating expenses4.21315316242282220r17
Operating income−4.2−12−15−1.8−63−25−27−22−10r−16
Interest and finance income0.00.00.00.00.11.00.2———
Interest expense and finance costs0.00.000.61.70.60.80.70.80.7
Other non-operating income (expense)−1.32.5−1.9−0.5−1.60.80.3−0.6−0.6−0.8
Income before tax−5.6−9.7−17−2.4−64−25−26—−12−17
Income tax−0.60.000.2000000
Net income attributable to shareholders−4.9−9.7−17−2.6−64−25−26−22−11r−17
Earnings per share, basic-0.79-4.75-10.55r-0.56-21.70r-0.28-0.46-0.54-1.09r-149.37
Earnings per share, diluted-0.79-4.75-10.55r-0.56-21.70r-0.28-0.46-0.54-1.09r-149.37
Shares, weighted average (basic)6.32.01.6r4.63.0r87————
Shares, weighted average (diluted)6.32.01.6r4.63.0r875841100.1
Balance sheet
Cash and cash equivalents3.7130.88.6353348262620
Short-term investments———04.549620——
Receivables————00.00.000—
Other current assets0.80.61.21.54.54.22.01.4r1.8r0.4
Current assets4.6142.01044861132828r20
Property, plant and equipment0.30.00.12.53.94.12.11.11.30.5
Right-of-use (leased) assets0.106.57.38.08.60.40——
Goodwill4.40————————
Other intangible assets3.80————————
Total assets14151223651001152929r21
Accounts payable1.71.01.60.43.41.91.80.51.00.5
Debt due within a year——006.905.0001.2
Current liabilities3.93.12.51.63414312.03.4r12
Long-term debt————01704.94.94.5
Lease liabilities (non-current)05.26.06.87.48.00.10——
Total liabilities108.38.58.45439357.89.0r18
Retained earnings−204−199−190−173−170−106−81−55−34r−23
Shareholders' equity3.96.83.0151162812120r2.4
Total liabilities and equity14151223651001152929r21
Shares outstanding6.46.01.8r5.03.6r888644390.1
Cash-flow statement
Depreciation and amortization0.20.00.61.21.10.80.40.40.20.2
Share-based compensation0.00.01.31.42.92.21.81.81.50.7
Cash from operating activities−8.6−2.9−10−36−35−391.3−19−20−5.1
Capital expenditure−0.000−0.0−1.0−3.2−1.1−0.1−0.9−0.4
Cash from investing activities−1.80−1.14.74310−63−0.1−0.9−0.4
Debt issued————0180—06.0
Debt repaid——0−7.5−10−5.000−1.00
Shares issued1.6125.45.011r3.09122320
Cash from financing activities1.6133.7−3.11.1158420276.3
Change in cash−8.810−7.8−349.4−14220.56.10.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K/A10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Exicure, Inc. sells: revenue by product line, fiscal 2024#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Biotechnology$1 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2024

Executive pay at Exicure, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2024
$374 K
Other top executives, average
$88 K
the CEO earned 4.3× this
$100 invested is now
$53
Exicure, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2024Chief executive$374 K$374 K$88 K$53
2023Chief executive$797 K$1.1 M$511 K$10

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024

Events at Exicure, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 2 · Auditor changed 1 · Directors and officers 9 · Material agreement 4 · Unregistered share sale 1 · Shareholder vote 1 · Results announced 4

Exicure, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Material agreement8-K
Auditor changed8-K
Results announced8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 acquisitions, $8 M paid where reported · 1 private funding rounds before listing

Businesses it acquired

Acquisitions by Exicure, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
GPCR USA2025—$8 M100%Annual report

Private share sales · funding history

Private share sales of Exicure, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$22 MNo. 1$10 to $50 million39equitySEC
Sep 2017$43 MIssued in a merger or acquisition$10 to $50 million84equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Exicure, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2021–2022
Latest
—
2022-09-23
Exicure, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022············—
2021············—
Exicure, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
66% of workforceRestructuring planSEC 8-K“On September 26, 2022, the Company announced its commitment to a plan to wind down the Company’s existing preclinical programs, including the development of its SCN9A product candi…”Filing
50% of workforceRestructuring planSEC 8-K“This plan will implement a reduction in force where the Company will eliminate approximately 50% of the Company’s existing workforce on a staggered basis through January 2022 as we…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Exicure, Inc. compares in Biotechnology

  • Market cap$6 M · higher than 6% of 726
  • Price / book1.5× · lower than 67% of 534
  • FCF yield-144.3% · higher than 5% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Exicure, Inc.🇺🇸$6 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Exicure, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Exicure, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Exicure, Inc.? Suggest a correction